http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021310011-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7485e30026433530b76e82c50219516a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8157d4945776664f631f7841cfe5841b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-90 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-20 |
| filingDate | 2019-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9044bd323ba9013970e930a7c1de2d71 |
| publicationDate | 2021-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2021310011-A1 |
| titleOfInvention | The gene therapy dna vector gdtt1.8nas12 and the method for obtaining thereof |
| abstract | The invention can be used in biotechnology, in particular to the gene therapy DNA vector GDTT1.8NAS12, Escherichia coli strain JM 110-NAS, Escherichia coli strain JM 110-NAS/GDTT1.8NAS12, and the industrial production of the gene therapy DNA vector GDTT1.8NAS12. A method of obtaining the gene therapeutic DNA vector GDTT1.8NAS12 involves construction of a 2408-bp intermediate vector containing a 688-bp replication origin, a 467-bp transcription terminator hGH-TA, a 137-bp regulatory site RNA-out transposon TnlO, a 1018-bp kanamycin resistance gene, and a 68-bp polylinker. Then, it is splitted using restriction endonucleases SalI and BamHI and ligated to the promoter regulatory region containing the 1219-bp promoter region of the human elongation factor EF1A with its own enhancer. The kanamycin resistance gene is cleaved at the SpeI restriction sites. |
| priorityDate | 2018-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 652.